The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics

Bibliographic Details
Title: The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics
Authors: Yan Fang, Hongming Yang, Guiming Hu, Jiakun Lu, Jun Zhou, Na Gao, Yuhan Gu, Cunzhen Zhang, Jinhuan Qiu, Yuanyuan Guo, Yunfei Zhang, Qiang Wen, Hailing Qiao
Source: Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-17 (2022)
Publisher Information: BMC, 2022.
Publication Year: 2022
Collection: LCC:Medicine
Subject Terms: Hepatocellular carcinoma, POR, Polymorphisms, HPN, Proteomics, Medicine
More Details: Abstract The effect of the cytochrome P450 oxidoreductase (POR) rs10954732 (G > A) polymorphism on hepatocellular carcinoma (HCC) susceptibility is unknown. Here we found that A allele carriers showed a 69% decrease in susceptibility to HCC with overall survival (OS) prolonged to 199%, accompanied by lower activity for cytochrome P450 2E1. A total of 222 differentially expressed proteins were mainly enriched in neutrophil and T cell activation and involved in the immune and inflammatory responses, constituting the altered immune tumor microenvironment related with A allele by proteomics analysis. Hepsin (HPN) showed significant down-regulation in HCC and up-regulation in A allele carriers. A lower HPN level was associated with increased susceptibility to HCC and a worse prognosis. Moreover, HPN is a potential independent prognostic biomarker for HCC and is strongly associated with clinicopathological features, tumor-infiltrating status of immune cells both in our discovery cohort and database surveys. Our findings provide a new potential mechanism by which HPN may play an important role in the susceptibility of rs10954732 A allele carriers to HCC and their prognosis through tumor immune infiltration, thus offering potential insights for future studies on tumor immunotherapy.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1479-5876
Relation: https://doaj.org/toc/1479-5876
DOI: 10.1186/s12967-022-03282-1
Access URL: https://doaj.org/article/2033194e2c7449e9a707cddc596dcd12
Accession Number: edsdoj.2033194e2c7449e9a707cddc596dcd12
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:14795876
DOI:10.1186/s12967-022-03282-1
Published in:Journal of Translational Medicine
Language:English